CV
Univ. Prof. Dr. med. H. Christian Reinhardt
Academic education
1996 - 2003: Medical School, University of Hamburg, Humboldt University Berlin and University of Freiburg
Scientific degrees
05/2012: Professor for Clinical and Molecular Oncology (W2), University Hospital Cologne
11/2008: Habilitation in Experimental Internal Medicine, University of Cologne
06/2003: MD thesis, Department of Internal Medicine, Division 4, University of Freiburg, Advisor: Prof. Dr. H. Pavenstädt (Grade: Summa cum laude)
06/2003: Graduation from Medical School, University of Freiburg (Grade: Summa cum laude)
Scientific career
11/2018: Speaker of the Mildred-Scheel School of Oncology Cologne-Bonn
6/2017: Executive attending physician at the Medical Clinic I of the University Hospital Cologne
3/2017: Speaker of the Else Kröner Forschungskolleg: Clonal evolution in cancer
6/2016: Certified Clinical Trials Manager
08/2015: Attending physician (Oberarzt) at the Medical Clinic I, University Hospital Cologne
05/2015: Board exam (certified in general internal medicine and hematology/medical oncology)
01/2015: Elected member of the executive board of the Center for Molecular Medicine Cologne
01/2013: Head of the Clinical Research Unit-286 “Exploiting defects in the DNA damage response for the treatment of chronic lymphocytic leukemia”
01/2012: Elected member of the steering committee of the Helmholtz Alliance Preclinical Comprehensive Cancer Center (PCCC)
06/2012: Scientific coordinator of Research Area C within the Excellence Cluster CECAD
01/2012: Lichtenberg Professor for Clinical and Molecular Oncology, University Cologne
11/2009: Emmy-Noether research group leader at the Medical Clinic I, University Cologne
12/2004 - 10/2009: Postdoctoral Associate, MIT, Department of Biology, Koch Institute (Profs. M. B. Yaffe, MD, PhD and T. Jacks, PhD)
01/2004 - 11/2004: Postdoctoral Research Fellow, University of Münster (Prof. H. Pavenstädt)
06/2003 - 12/2003: Postdoctoral Research Fellow University of Freiburg, (Profs. G. Walz and T. Benzing)
Honors/ Awards/ Memberships
2017: Gilead Research Award Oncology
2016: Theodor Frerichs Award of the German Society of Internal Medicine
2012: GlaxoSmithKline Research Award
2011: Vincenz Czerny Award of the German Society for Hematology and Oncology
2011: W2 Lichtenberg Professorship of the VolkswagenStiftung
2011: Research Award of the Central European Society for Anticancer Drug Research
2011: Johann-Georg-Zimmermann Award for Cancer Research
2010: Young Leaders in Science Award of the Schering Stiftung
2009: Emmy-Noether fellowship of the Deutsche Forschungsgemeinschaft
2009: Startup grant Ministerium für Innovation, Wissenschaft, Forschung und Technologie, NRW
2009: NIH/NCI K99/R00 PI award (relinquished due to return to Germany)
2007: MIT-Koch Award
2005: Research fellowship of the Deutsche Forschungsgemeinschaft
2004: Young investigator award of the Deutsche Nierenstiftung
10 most relevant publications
- Janes KA*, Reinhardt HC*, and Yaffe MB. Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell2008 Oct 17;135(2):343-54.*equal contribution
- Jachimowicz RD, Beleggia F, Isensee J, Bhavana VB, Goergens J, Bustos MA, Doll MA, Shenoy A, Checa-Rodriguez C, Wiederstein JL, Baranes-Bachar K, Bartenhagen C, Hertwig F, Teper N, Nishi T, Schmitt A, Distelmaier F, Lüdecke HJ, Albrecht B, Krüger M, Schumacher B, Geiger T, Hoon DSB, Huertas P, Fischer M, Hucho T, Peifer M, Ziv Y, Reinhardt HC*#, Wieczorek D*, Shiloh Y*:UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors, Cell, in press, * Shared last authors, #lead author contact
- Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun A, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC. A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell. 2015 Jul 2; 1; 146-159
- Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov. 2014 May;4(5):592-605
- Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas JM, Chen S, Reinhardt HC. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med. 2013 Jun 12;5(189)
- Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen P-H, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Büttner R, Persigehl T, Reinhardt HC: Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nature Communications, 2017 Jul 28;8(1):153. doi: 10.1038/s41467-017-00210-6.
- Reinhardt HC, Aslanian AS, Lees JA, and Yaffe MB. p53 deficient cells rely on ATM and ATR-mediated checkpoint signaling through the p38 MAPK/MK2 pathway for survival after DNA damage. Cancer Cell. 2007 Feb;11(2):175-89.
- Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt M, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB. DNA Damage activates A Spatially Distinct Late Cytoplasmic Cell Cycle Checkpoint Network Controlled by MK2-mediated RNA Stabilization. Mol Cell. 2010 Oct 8;40(1):34-49
- George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Nguyen C, Berg J, Müller C, Dahmen I, Jahchan N, Yang D, Karnezis AN, Vaka D, Torres A, Menon R, Wang MS, Stuetz A, Korbel J, Wilkerson M, Hayes N, Engelmann D, Pützer B, Vlasic I, Seidel D, Pinther B, Schaub B, Becker C, Altmüller J, Yokota J, Khono T, Iwakawa R, Muley T, Peterson I, Chen Y, Soltermann A, Tischler V, Massion P, Zou Y, Wright GM, Russell P, Solomon B, Koch I, Field JK, Muscarella LA, La Torre A, Jakopovic M, Knezevic J, Heiden E, Roz L, Jovanovic D, Kontic M, Thunnissen E, Köhler J, Schuler M, Sanchez-Cespedes M, Salvesen H, Achter V, Bogus M, Schneider P, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt HC, Perner S, Heukamp LC , Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK. Comprehensive genomic profiling of small cell lung cancer. Nature. 2015 Aug 6;524(7563):47-53.
- Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB. 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007 Mar 15;446(7133)
Patents
- Inventors: Michael B. Yaffe, Isaac A. Manke, Daniel Lim, Hans Christian Reinhardt, USPTO Application #:20090010927
Title: MAPKAP KINASE-2 AS A SPECIFIC TARGET FOR BLOCKING PROLIFERATION OF P53-DEFECTIVE CELLS
Abstract: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders
Contact Information
Univ. Prof. Dr. med. H. Christian Reinhardt
Professor for Clinical and Molecular Oncology (W2) and attending physician (Oberarzt)
University Hospital of Cologne
Department I for Internal Medicine
